

NOTICES

Notice No.	20250428-9	Notice Date	28 Apr 2025
Category	Company related	Segment	Equity
Subject	Rights Entitlements of REMEDIUM LIFECARE LIMITED		
Content			

Trading Members of the Exchange are hereby informed that dealings in the Rights Entitlements (REs) for Renunciation of REMEDIUM LIFECARE LIMITED are permitted on the Exchange with effect from **Wednesday, April 30, 2025**. The details of Rights Entitlements (REs) are as under:

Name of the Company	REMEDIUM LIFECARE LIMITED
Type of Security	Rights Entitlements (REs)
Trading period for Renunciation of Rights Entitlements (REs)	Wednesday, April 30, 2025 to Friday, May 09, 2025.
Scrip Code	750974
Scrip ID	REMLIF-RE
ISIN No.	INE549S20010
Market Lot	1
Group	R

Please note that the Rights Issue will open on April 30, 2025 to May 14, 2025.

Trading Members are further requested to note that Rights Entitlements (REs) for Renunciation shall be settled on T+1 Rolling Settlement basis. The trades shall be settled on trade-for-trade basis. The Rights Entitlements shall be tradable in dematerialized form only. Trading members shall inform all its clients about the commencement of trading in REs mentioning the ISIN of the RE and that the same shall not be mistaken for ordinary shares of the concerned company. Trading members shall include a disclaimer prominently in the contract notes / bill containing purchase of REs informing the Clients that the purchase of REs only gives them the right to participate in the ongoing Rights Issue of the concerned company by making an application with requisite application money or renounce the REs before the issue closes. REs which are neither subscribed by making an application with requisite application money nor renounced, on or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

Trading Members are requested to refer the notice no- 20200305-21 dated March 05, 2020 and notice no-20200518-34 dated May 18, 2020 for further details.

Mangesh Tayde
Deputy General Manager